

Applicant: Soon-Shiong and Desai
Application No.: 09/628,387
Filed: August 1, 2000
Page 3

PATENT
Attorney Docket No.: ABI1150-18

IN THE CLAIMS

Please amend claims 1-3, 16, 58-60, 128, and 145 as set forth herein, and cancel claims 4-11, 30-44, 61-73, 98-101, 104-107, 110-113, 116-119, 122-125, 133-141, 149-151, 153-158, 160-162, and 164-177 without prejudice. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A unit dosage form comprising a sealed vial containing a sufficient quantity of cremophor-free taxane to provide for administration to a human subject a total dose of taxane in the range of about 30 mg/m² to about 1000 mg/m² over an administration period no greater than about 3 hours, wherein the cycle time between administrations of said total dose is less than about three weeks.

2. (Currently Amended) A unit dosage form according to claim 1, wherein said total dose is in the range of about ~~80~~ 50 mg/m² to about 700 mg/m².

3. (Currently Amended) A unit dosage form according to claim 1, wherein said total dose is in the range of about ~~50~~ 175 mg/m² to about ~~800~~ 300 mg/m².

4-11. (Cancelled)

12. (Original) A unit dosage form according to claim 1, wherein said taxane is administered locally.

13. (Original) A unit dosage form according to claim 1, wherein said taxane is administered systemically.

14. (Original) A unit dosage form according to claim 1, wherein said taxane is in a non-aqueous formulation.

Applicant: Soon-Shiong and Desai
Application No.: 09/628,387
Filed: August 1, 2000
Page 4

PATENT
Attorney Docket No.: ABI1150-18

15. (Original) A unit dosage form according to claim 1, wherein said taxane is docetaxel.

16. (Currently Amended) A unit dosage form according to claim 1, wherein said taxane is a paclitaxel analog.

17-57. (Cancelled)

C¹
cont

58. (Currently Amended) A unit dosage form comprising a sealed vial containing a sufficient quantity of cremophor-free taxane to provide for administration to a human subject a total dose of taxane in the range of about ~~30 mg/m² to about 1000 mg/m²~~, wherein said sealed vial comprises in the range of about 4 mg to about 822 mg of said taxane over an administration period of no greater than 3 weeks, wherein the cycle time between administrations of said total dose is less than about three weeks.

59. (Currently Amended) A unit dosage form according to claim 58, wherein said sealed vial total dose comprises in the range of about 4 30 mg to about ~~13~~ 700 mg of said taxane.

60. (Currently Amended) A unit dosage form according to claim 58, wherein said sealed vial total dose comprises in the range of about ~~13~~ 100 mg to about ~~30~~ 400 mg of said taxane.

61-73 (Cancelled)

74. (Original) A unit dosage form according to claim 58, wherein said taxane is administered locally.

75. (Original) A unit dosage form according to claim 58, wherein said taxane is administered systemically.

76. (Original) A unit dosage form according to claim 58, wherein said taxane is in a non-aqueous formulation.

Applicant: Soon-Shiong and Desai
Application No.: 09/628,387
Filed: August 1, 2000
Page 5

PATENT
Attorney Docket No.: ABI1150-18

77. (Original) A unit dosage form according to claim 58, wherein said taxane is docetaxel.

78. (Original) A unit dosage form according to claim 58, wherein said taxane is a paclitaxel analog.

79-127. (Cancelled)

C1
cont

128. (Currently Amended) A cremophor-free taxane containing formulation contained within a sealed vial suitable for the delivery to a human subject of a total dose of taxane in the range of about 30 mg/m² to about 1000 mg/m², with an administration period of no greater than about 3 hours, wherein the cycle time between administrations of said total dose is less than about three weeks.

129. (Original) A formulation according to claim 128, wherein said total dose of taxane is in the range of about 80 mg/m² to about 700 mg/m².

130. (Previously Amended) A formulation according to claim 128, wherein said taxane is docetaxel.

131. (Original) A formulation according to claim 128, wherein said taxane is a paclitaxel analog.

132-144. (Cancelled)

145. (Currently Amended) A method for administration of cremophor-free taxane to a human subject in need thereof, said method comprising administering in the range of about 30 mg/m² to about 1000 mg/m² of said taxane to said subject in a pharmaceutically acceptable formulation contained within a sealed vial with a treatment cycle no greater than about 3 weeks, wherein said administration period is no greater than about 3 hours.

146. (Previously Amended) A method according to claim 145, wherein said taxane is docetaxel.

MAY. 9. 2003 3:39PM

858 792-6773 FOLEY AND LARDNER

NO. 0042 P. 12

Applicant: Soon-Shiong and Desai
Application No.: 09/628,387
Filed: August 1, 2000
Page 6

PATENT
Attorney Docket No.: ABI1150-18

C! cancelled.
147. (Original) A method according to claim 145, wherein said taxane is a paclitaxel analog.

148-177. (Cancelled)